Skip to main content
Category

News Archive

brian-darmody-2-umd-image

Maryland: The state of research – Maryland Daily Record

By News Archive

brian-darmody-2-umd-image

Which state has the nation’s most research-intensive economy? California? Massachusetts? North Carolina?

Actually it’s Maryland. A greater portion of Maryland’s economy comes from private, federal, and university research spending than any state (with the exception of rural New Mexico with its two large federal labs).  But not enough of us recognize that.

Read More
nhlbi-nih-logo

NHLBI Funding & Research Opportunities and Announcements for February 10, 2017

By News Archive

nhlbi-nih-logo

Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

Notices:

  • Impact of Washington, DC Area Federal Office Operating Status on NIH Grant Application Due Dates 
  • Notice of NIA’s Participation in PA-17-101 “Research on the Health of Women of Underrepresented, Understudied and Underreported (U3) Populations – An ORWH FY17 Administrative Supplement (Admin Supp)”
  • NHLBI Priorities for HIV Research and Funding 
  • Notice of NLM’s Participation in PA-17-101 “Research on the Health of Women of Underrepresented, Understudied and Underreported (U3) Populations An ORWH FY17 Administrative Supplement (Admin Supp)”
emergent-biosolution-logo

Emergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics

By News Archive

emergent-biosolution-logo

Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $30.5 million to develop monoclonal antibody therapeutics for viral hemorrhagic fever. This task order will utilize the company’s Center for Innovation in Advanced Development and Manufacturing (CIADM) facility located in Baltimore, Maryland. Using monoclonal antibodies from Mapp Biopharmaceutical Inc., the company will conduct technology transfer of process materials and information, perform process and analytical method development, execute small-scale production runs, and perform cGMP cell banking leading to cGMP manufacture of bulk drug substance. The task order consists of a 36-month period of performance with a base task order valued at $7.4 million and options that, if executed, will bring the total task order value over three years to up to $30.5 million.

Read More
national-mall-dc-pixa

‘March for Science’ Organizer Says It’s About the Public, Not the Scientists – The Chronicle of Higher Education

By News Archive

national-mall-dc-pixa

Scientists are no strangers to having their work questioned by lawmakers, and now they are fighting back.

On April 22, scientists and their supporters will hold a March for Science to advocate for science and evidence-based research in policies. The main march will be held in Washington, D.C., and satellite marches will be held in other cities, as they were with the Women’s March the day after the inauguration. And the march’s organizers say they aren’t just fighting for more funding for science, or more influence in policy, but also to raise awareness about the type of research they’re doing.

Read More
white-house-washingington-dc-pixa

What’s Happening with the Affordable Care Act?

By News Archive

white-house-washingington-dc-pixa

The recent flurry of activity around the Affordable Care Act (ACA) has many people confused about where it stands, and what the employer’s obligations are. The following summarizes the activity so far.

Legislative Repeal Activity

A popular meme suggests that the Senate voted to eliminate virtually all of the provisions of the ACA, including the ability to obtain insurance in spite of pre-existing conditions, the requirement to cover adult children up to the age of 26, etc. This is not the case.

Read More
us-hhs-gov-logo

Trump’s pick for health and human secretary takes office

By News Archive

us-hhs-gov-logo

President Donald Trump’s new health secretary took office Friday after becoming the latest Cabinet nominee to eke out a confirmation victory in the bitterly divided Senate.

Vice President Mike Pence administered the oath of office to Tom Price, of Georgia, at the White House hours after the Senate confirmed him 52-47 in a party-line vote. That roll call came in the dead of night, thanks to Democrats’ tactic of forcing prolonged debates to broadcast their opposition to Trump and his team.

Read More
umd-maryland-logo

University of Maryland researchers make strides in schizophrenia diagnosis research – EurekAlert! Science News

By News Archive

umd-maryland-logo

Researchers from the University of Maryland College Park (UMD) and Baltimore (UMB) campuses have developed a blood test that could help doctors more quickly diagnose schizophrenia and other disorders. Their study, “Redox Probing for Chemical Information of Oxidative Stress,” was recently published in the journal Analytical Chemistry.

“We hope our new technique will allow a more rapid detection and intervention for schizophrenia, and ultimately lead to better outcomes,” said Gregory Payne, one of the authors and a joint professor with UMD’s Fischell Department of Bioengineering (BIOE) and the Institute for Bioscience and Biotechnology Research (IBBR).

Read More
surgigyn-logo

UM Baltimore, SurgiGyn ink licensing deal for laparoscopic hysterectomy device – MassDevice

By News Archive

surgigyn-logo

Gynecological surgery device developer SurgiGyn said today it inked an exclusive license arrangement with the University of Maryland, Baltimore for laparoscopic surgical device technology developed at the University.

The Baltimore, Md.-based company said it also closed a seed round of funding from UM Ventures and a private investor, with funds slated to support accelerated development of its uterine electrosurgical device

Read More
bio new logo

BIO Statement on President Trump’s Comments Supporting Biopharmaceutical Competition and Innovation – BIO

By News Archive

bio-new-logo

The Biotechnology Innovation Organization (BIO) issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:

“We look forward to working with President Trump and his team to enact policies that ensure better access to and affordability of today’s medicines and the vision the President laid out in his inaugural address ‘….to free the earth from the miseries of disease, and to harness the energies, industries and technologies of tomorrow.’ The ideas the President laid out in his meeting today–policies that would cut unnecessary regulation, enforce fair trade, increase competition, support small companies’ ability to attract capital and strengthen and promote market-based solutions–are ideas that BIO has been advocating for and working to build consensus on with others in the healthcare system.  They will go a long way toward ensuring that patients have affordable access to today’s innovative medicines and that our companies have the policy and regulatory environment they need to bring a new generation of breakthrough medicines to our children and grandchildren.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.